Friday, 12 December 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 12 December 2025
News

Pfizer unveils new obesity play

Posted 11 December 2025 AM 

Fresh from winning the bidding war for Metsera, Pfizer has made another move into the obesity market, signing a collaboration and licence agreement for a GLP-1 pill being developed by YaoPharma.

Pfizer will pay US$150 million up front and as much as US$1.94 billion in developmental, regulatory and commercial milestone payments for the small-molecule GLP-1 receptor agonist YP05002, it announced on Tuesday. YaoPharma will also be eligible for royalties if the drug reaches the market.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.